Publications in collaboration with researchers from Instituto de Investigación Sanitaria de Navarra (18)

2024

  1. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer

    Cancers, Vol. 15, Núm. 12

  3. Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

    Clinical cancer research : an official journal of the American Association for Cancer Research

  4. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

  5. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors

    Journal of Controlled Release, Vol. 357, pp. 67-83

2022

  1. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

  2. Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists

    Biomedicines, Vol. 10, Núm. 7

  3. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

  4. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

  5. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

  6. YES1 Is a Druggable Oncogenic Target in SCLC

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403

2021

  1. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

2020

  1. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

  2. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2019

  1. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  2. Programmed death–ligand 1 expression on direct Pap-stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens

    Cancer Cytopathology, Vol. 127, Núm. 7, pp. 470-480

2015

  1. Sphere-derived tumor cells exhibit impaired metastasis by a host-mediated quiescent phenotype

    Oncotarget, Vol. 6, Núm. 29, pp. 27288-27303